Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study

Roubaud G., Oezgueroglu M., Penel N., Matsubara N., Mehra N., Kolinsky M. P., ...More

EUROPEAN JOURNAL OF CANCER, vol.170, pp.73-84, 2022 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 170
  • Publication Date: 2022
  • Doi Number: 10.1016/j.ejca.2022.04.016
  • Journal Name: EUROPEAN JOURNAL OF CANCER
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, BIOSIS, CAB Abstracts, CINAHL, EMBASE, Gender Studies Database, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.73-84
  • Keywords: PROfound, Metastatic castration-resistant prostate, cancer, Olaparib, Safety, Adverse-event management, RELAPSED OVARIAN-CANCER, MAINTENANCE THERAPY, MUTATION, CHEMOTHERAPY
  • Istanbul University Affiliated: No

Abstract

Background: Based on PROfound, olaparib is approved for patients with metastatic castration-resistant prostate cancer following disease progression on at least enzalutamide or abiraterone and who carry relevant alterations in DNA repair genes. To facilitate continued olaparib treatment as long as the patient derives benefit, we describe further safety assessments from PROfound focusing on the four most common adverse events (AEs) and events of special interest.